Form 4: Lifecore Biomedical Director Houde Lovas Katrina Acquires 30,000 Shares

Director Houde Lovas Katrina reports acquisition of 30,000 shares of Lifecore Biomedical, Inc.

Summary

• On July 8, 2024, Katrina Houde Lovas, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• Following the transaction, Houde Lovas directly owns 89,906 shares of Lifecore Biomedical, Inc.
• The shares were acquired in the form of restricted stock units that convert into common stock on a 1 for 1 basis.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's share acquisition, which can be interpreted as a slightly positive signal but doesn't provide strong evidence for a bullish or bearish outlook.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is tied to the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration, indicating a future event that will convert the units to common stock.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders may view the director's share acquisition as a positive sign of confidence in the company.

Key Dates